SEC Form 4 · accession 0001213900-18-005373
NEXEON MEDSYSTEMS INC · NXNN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
ROSELLINI SCIENTIFIC LLC
10% Owner
Period of report
Oct 9, 2017
Accepted (ET)
May 1, 2018 · 8:12 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001416172
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| COMMON STOCKF1 | Oct 9, 2017 | J | 81,035 | $0.838 | A | 12,624,842 | D | |
| COMMON STOCKF2 | Dec 12, 2017 | J | 420,000 | $0.952 | A | 13,044,842 | D | |
| COMMON STOCKF3 | Dec 29, 2017 | J | 61,884 | $0.838 | A | 13,106,726 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On October 9, 2017, the Issuer issued 81,035 shares of restricted common stock to Rosellini Scientific, LLC ("RS"), as repayment for 81,035 shares of the Issuer's restricted common stock RS loaned to Nexeon Medsystems Belgium, SPRL, a wholly owned subsidiary of the Issuer, for payment of outstanding vendor invoices.
- F2Rosellini Scientific, LLC received 420,000 shares of the Issuer's restricted common stock from an individual as repayment for a loan to the individual in the amount of $400,000 ($0.952 per share).
- F3On December 29, 2017, the Issuer issued 61,884 shares of restricted common stock to RS in settlement for a cash loan to NMB from RS and for an adjustment to the market value of the 81,035 shares described above per the debt repayment agreement dated December 29, 2017. In total, the 142,919 shares were valued $119,746 ($0.838 per share).